MD, PhD, Founder, Chairman and Chief Executive Officer of Ionis Pharmaceuticals Akcea Therapeutics, 22 Boston Wharf Rd, 9th Fl, Boston, Massachusetts 02210, United States. It is a well-known fact ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Ionis will be pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS. Olezarsen is an RNA-targeted investigational ligand conjugated antisense (LICA ...

Ionis Pharmaceuticals ... ligand conjugated ASOs or LICA tissue targeting; (ii) the targeted intracellular distribution; (iii) the design of ASOs to take advantage of newly identified molecular ...

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: A live ...

Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis ...